Literature DB >> 4035676

Comparison of the severity of the chronic cardiotoxicity produced by doxorubicin in normotensive and hypertensive rats.

E H Herman, A N el-Hage, V J Ferrans, B Ardalan.   

Abstract

A comparison was made of the severity of chronic doxorubicin cardiotoxicity in adult male spontaneously hypertensive rats (SHR) and in genetically related normotensive Wistar-Kyoto rats (WKY). Groups of SHR and WKY were given 12 weekly iv injections of doxorubicin at 0.25, 0.5, or 1.0 mg/kg. When the study was concluded, mean arterial pressure was 127 to 161 nm Hg in doxorubicin-treated SHR compared with 74 to 87 mm Hg in similarly treated WKY. Lesions, consisting mainly of cytoplasmic vacuolization and myofibrillar loss, were noted in the hearts from both types of rats given the 1.0-mg/kg dose and were considerably more severe in SHR than in WKY (average scores 3.8 and 2.0). Renal lesions (glomerular vacuolization and dilatation of tubules with accumulations of proteinaceous material) were of comparable severity in both types of rats at the 9- and 12-mg/kg cumulative doses; however, they were more severe in SHR at the 6-mg/kg cumulative dose. Moderate cardiac alterations were present in all SHR (average score 1.6) given 0.5 mg doxorubicin/kg; at the same dose, lesions were minimal in two and absent in three WKY. In a second study, groups of rats were killed 1 week after 3,6,9, or 12 weekly iv injections of doxorubicin (1.0 mg/kg). Myocardial lesions were noted initially in SHR after six doses and in WKY after nine doses. Three of five SHR were dead by the 12th dose. These results indicate that spontaneously hypertensive rats are much more sensitive than normotensive rats to the cardiotoxic effects of doxorubicin.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4035676     DOI: 10.1016/0041-008x(85)90284-4

Source DB:  PubMed          Journal:  Toxicol Appl Pharmacol        ISSN: 0041-008X            Impact factor:   4.219


  23 in total

1.  Cardiovascular risk factors in hematopoietic cell transplantation survivors: role in development of subsequent cardiovascular disease.

Authors:  Saro H Armenian; Can-Lan Sun; Tabitha Vase; Kirsten K Ness; Emily Blum; Liton Francisco; Kalyanasundaram Venkataraman; Raynald Samoa; F Lennie Wong; Stephen J Forman; Smita Bhatia
Journal:  Blood       Date:  2012-10-03       Impact factor: 22.113

Review 2.  Cardiomyopathy in Childhood Cancer Survivors: Lessons from the Past and Challenges for the Future.

Authors:  Matthew J Ehrhardt; Joy M Fulbright; Saro H Armenian
Journal:  Curr Oncol Rep       Date:  2016-04       Impact factor: 5.075

3.  Anthracycline cardiotoxicity: the importance of horizontally integrating pre-clinical and clinical research.

Authors:  Steven E Lipshultz; Eugene H Herman
Journal:  Cardiovasc Res       Date:  2018-02-01       Impact factor: 10.787

Review 4.  Cardiotoxicity in childhood cancer survivors: strategies for prevention and management.

Authors:  Danielle Harake; Vivian I Franco; Jacqueline M Henkel; Tracie L Miller; Steven E Lipshultz
Journal:  Future Cardiol       Date:  2012-07

5.  Anthracycline cardiotoxicity: from bench to bedside.

Authors:  Luca Gianni; Eugene H Herman; Steven E Lipshultz; Giorgio Minotti; Narine Sarvazyan; Douglas B Sawyer
Journal:  J Clin Oncol       Date:  2008-08-01       Impact factor: 44.544

Review 6.  Myocardial diseases of animals.

Authors:  J F Van Vleet; V J Ferrans
Journal:  Am J Pathol       Date:  1986-07       Impact factor: 4.307

7.  Timing of treatment with ICRF-187 and its effect on chronic doxorubicin cardiotoxicity.

Authors:  E H Herman; V J Ferrans
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

8.  Effects of ICRF-187 on the cardiac and renal toxicity of epirubicin in spontaneously hypertensive rats.

Authors:  M Dardir; E H Herman; V J Ferrans
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

9.  Protective effects of fructose-1,6-diphosphate on acute and chronic doxorubicin cardiotoxicity in rats.

Authors:  R Danesi; N Bernardini; A Marchetti; M Bernardini; M Del Tacca
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

10.  Comparison of the protective effects of desferrioxamine and ICRF-187 against doxorubicin-induced toxicity in spontaneously hypertensive rats.

Authors:  E H Herman; J Zhang; V J Ferrans
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.